Safety and Varicella Outcomes in In Utero–Exposed Newborns and Preterm Infants Treated With Varicella Zoster Immune Globulin (VARIZIG): A Subgroup Analysis of an Expanded-Access Program

Jennifer M. Duchon,1,2 Myron J. Levin,3,4 and Anne A. Gershon5

1Division of Pediatric Infectious Diseases, Tufts Floating Hospital for Children, Boston, Massachusetts, USA, 2Division of Newborn Medicine, Tufts Floating Hospital for Children, Boston, Massachusetts, USA, 3Department of Pediatrics (Infectious Diseases), University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA, 4Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA, and 5Department of Pediatrics–Infectious Diseases, Columbia University College of Physicians and Surgeons, New York, New York, USA

Background. Infants exposed to varicella zoster virus (VZV) in utero ≤5 days before or ≤48 hours after delivery and preterm infants are at high risk for varicella complications. An expanded-access program assessed varicella outcomes after administration of varicella zoster immune globulin (human) (VARIZIG) in a real-world setting.

Methods. In this open-label, expanded-access program, high-risk infants received ≤125 IU/10 kg of VARIZIG (NCT00338442). VZV outcomes and safety were assessed.

Results. There were 43 newborns exposed to VZV in utero and 80 preterm infants exposed to VZV; >80% received VARIZIG within 96 hours of reported exposure. When varicella outcomes were available, varicella occurred in 7 of 38 (18%) in utero–exposed newborns and zero of 65 preterm infants. Varicella-related complications were reported in 3 in utero–exposed newborns (3 with >100 lesions, 1 each with encephalitis and pneumonia). Adverse events were reported for 16% of in utero–exposed newborns and 25% of preterm infants, but few were considered related to VARIZIG. There were no deaths attributable to varicella or VARIZIG.

Conclusions. Varicella incidence and morbidity were low in in utero–exposed infants and zero in preterm infants who received prophylactic VARIZIG. There were few VARIZIG-related safety concerns.

Keywords. hyperimmune globulin; passive immunization; postexposure; preterm; varicella.

Received 1 May 2019; editorial decision 24 September 2019; accepted 2 October 2019. Published online November 27, 2019.

Corresponding Author: Jennifer M. Duchon, MDCM, MPH, Tufts Floating Hospital for Children, Boston, MA 02111. Email: jduchon@tuftsmedicalcenter.org.

Journal of the Pediatric Infectious Diseases Society 2019;XX(XX):1–5 © The Author(s) 2019. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com DOI: 10.1093/jpids/piz070

VARIZIG in Infants and Neonates • JPIDS 2019:XX (XX XXXX) • 1
soon as possible after VZV exposure, ideally within 96 hours, but up to 10 days after exposure [18]. Levin et al have recently reported on results from an expanded-access program that assessed the incidence and severity of VARIZIG in a real-world setting in several high-risk populations, including infants aged <1 year [20]. Given the limited published information with VARIZIG, we report here a more detailed analysis of clinical and safety outcomes in subgroups of infants exposed to VZV in utero or of preterm infants.

METHODS

This was an open-label, expanded-access program in which infants received ≤125 IU/10 kg of VARIZIG administered intramuscularly, ideally within the first 96 hours postexposure, but up to 10 days postexposure (NCT00338442). The initial protocol allowed for infants weighing <5 kg to receive a reduced VARIZIG dose (≤62.5 IU). Participants in the full expanded-access program were physician-identified high-risk individuals who had been exposed to varicella or herpes zoster, including immunocompromised children and adults, pregnant women, healthy nonimmune adults, and infants [20]. For the current analysis, we further assessed varicella outcomes and safety metrics of VARIZIG administered to infants who were stratified into 2 subgroups: newborns born to mothers who developed VZV infection within 5 days before birth or within 48 hours after birth and preterm infants (≤28 weeks' gestation). Infants were followed from initial VARIZIG administration with 3 additional visits through a maximum of 42 days to determine the incidence and severity of varicella and any varicella-related complications (eg, pneumonia, encephalitis, or mortality). Per study definition, varicella cases were considered severe when the lesion count was >100. Parent/caregiver-reported and investigator-reported adverse events (AEs) were included in the safety evaluation. Additional study design details have been previously reported [20].

This study was conducted in accord with the Good Clinical Practice Guidelines as defined by the International Conference on Harmonisation, the Declaration of Helsinki, and/or all applicable federal and local regulations and institutional review boards, as appropriate. All infants had parent/caregiver-provided written informed consent.

RESULTS

Participants

Forty-three newborns exposed to VZV in utero and 80 preterm infants were enrolled in the study (Table 1). In utero–exposed newborns had a mean age of 2.2 (standard deviation [SD], 2.21) days at enrollment, were relatively evenly distributed between males and females, and 42% were Hispanic/Latino newborns. Newborns had a mean weight of 3.2 (SD, 0.82) kg. The mean age for preterm infants at the time of exposure was 36.4 days, with half (51%) of preterm infants aged <1 month and 13 (16%) aged 1 to <2 months. The majority of preterm infants were female (59%) and white (55%). The mean weight of preterm infants at the time of exposure was 1.9 (SD, 0.93) kg.

VZV Exposure

Nearly all (99%) preterm infants were exposed to VZV in a hospital setting (Table 2). Most (60%, n = 26) in utero–exposed newborns were exposed to varicella (maternal infection), although 14% (n = 6) were exposed to herpes zoster (maternal infection); 26% (n = 11) of in utero–exposed newborns did not have the specific type of VZV infection specified in their case report form. The preterm infant group reported similar rates of exposure to varicella or herpes zoster; 42% of preterm infants did not have the type of VZV infection specified in their case report form (Table 2). The duration of exposure in preterm infants reported by providers ranged from <15 minutes to 5 days, with 35% exposed for >12 hours, 25% exposed for 3–12 hours, and 31% exposed for <3 hours (14% were exposed for <1 hour). Duration of exposure for in utero–exposed newborns could not be calculated.

Varicella Outcomes

More than 80% of infants in each subgroup received VARIZIG within 96 hours of either delivery (if in utero exposure) or contact exposure (if preterm infants) (Table 2). For infants with available varicella outcome data, the incidence of varicella was 18% (7/38) for in utero–exposed newborns and 0% (0/65) for preterm infants (Figure 1). Maternal varicella infection led to varicella in 7 of 23 (30%) in utero–exposed newborns, whereas maternal

Table 1. Baseline Demographics

| Characteristic | In Utero–Exposed Newborns (n = 43) | Preterm Infants (n = 80) |
|---------------|-----------------------------------|-------------------------|
| Age at VARIZIG administration, d | | |
| Mean (SD) | 2.2 (2.21) | 36.4 (34.11)a |
| Median | 1.0 | 27.5 |
| Range | 0–9 | 1–180 |
| Sex, No. (%) | | |
| Female | 23 (53) | 47 (59) |
| Male | 20 (47) | 33 (41) |
| Race, No. (%) | | |
| White | 11 (26) | 44 (55) |
| Hispanic or Latino | 18 (42) | 14 (18) |
| Black or African American | 4 (9) | 15 (19) |
| Asian | 5 (12) | 2 (3) |
| Not reported/declined/other | 5 (12) | 5 (6) |
| Weight, kg | | |
| Mean (SD) | 3.2 (0.82) | 1.9 (0.93) |
| Median | 3.3 | 1.8 |
| Range | 1.0–4.7 | 0.5–6.7 |

Abbreviations: SD, standard deviation; VARIZIG, varicella zoster immune globulin, human. *Forty-one preterm infants (51%) were aged <1 month, 15 (19%) were 1 to <2 months old, 13 (16%) were 2 to <3 months old, 9 (11%) were 3 to <4 months old, and 2 (3%) were 4–6 months old.
herpes zoster infection did not result in varicella in the 6 newborns exposed to maternal herpes zoster in utero. Three newborns exposed in utero developed varicella-related complications; all 3 had >100 lesions, 1 developed encephalitis, and 1 developed pneumonia. No preterm infants developed varicella-related complications. Information on varicella outcome was not available for 5 in utero–exposed infants and 15 preterm infants. Nine infants weighing <5 kg received ≤62.5 IU of VARIZIG; of these infants, 7 did not develop varicella and 2 were lost to follow-up. One preterm infant was considered to be underdosed, having received 14 IU for a 1.2 kg infant; this preterm infant did not develop varicella.

Approximately one-quarter (28%) of in utero–exposed newborns received concomitant acyclovir prophylaxis, compared with only 4% of infants in the preterm group. If administered, concomitant acyclovir prophylaxis was begun on the day before or the day of VARIZIG administration in 72% of infants. Overall, 7 patients only received acyclovir prophylaxis for 2 or fewer days, presumably until VARIZIG was administered, whereas 7 others received acyclovir for a range of 4–9 days. Among the in utero–exposed newborns treated with acyclovir prophylaxis, 1 of 11 developed varicella; this newborn developed >100 lesions. In comparison, the remaining 6 in utero–exposed newborns who developed varicella did not receive acyclovir prophylaxis; 2 of these newborns had varicella-associated complications (1 had >100 lesions and pneumonia, 1 had >100 lesions and encephalitis).

### Safety

Overall, 22% of infants experienced an AE, of which 16% were in utero–exposed newborns and 25% in preterm infants (Table 3). Only 2 of these AEs were considered possibly related to VARIZIG.

Twelve percent of in utero–exposed newborns experienced 5 serious AEs (4 were cases of varicella), of which 1 case of varicella was labeled by an individual investigator as an AE possibly related to VARIZIG (ie, a lack of VARIZIG efficacy). Nine percent of preterm infants experienced 20 serious AEs, of which 1 seizure was considered possibly related to VARIZIG. There were 2 deaths reported, both of which occurred in premature infants (23 and 25 weeks’ gestation) and were caused by bronchopulmonary dysplasia and intraventricular hemorrhage; both deaths were considered unrelated to VARIZIG or varicella.

### Table 2. Exposure and Administration Details

| Characteristic | In Utero–Exposed Newborns (n = 43) | Preterm Infants (n = 80) |
|---------------|-----------------------------------|------------------------|
| **Source of VZV exposure** | | |
| In uterus | 43 (100) | 0 |
| Hospital | 0 (0) | 79 (99) |
| Household | 0 (0) | 1 (1) |
| **Type of VZV exposure** | | |
| Varicella | 26 (60) | 26 (33) |
| Herpes zoster | 6 (14) | 20 (25) |
| Not specified | 11 (26) | 34 (42) |
| **Timing of administration** | | |
| ≤96 hours postexposure | 37 (86) | 71 (89) |
| >96 hours postexposure | 6 (14) | 8 (10) |
| Unknown | 0 (0) | 1 (1) |
| **Concomitant antiviral prophylaxis** | | |
| Did not receive | 32 (74) | 77 (98) |
| Did receive | 11 (26) | 3 (4) |

Data are presented as No. (%).

*For in utero–exposed newborns, the type of VZV exposure refers to the maternal VZV infection.

*Timing of administration is calculated based on initial report of exposure. For in utero–exposed infants, this was considered to have occurred at birth or prior to birth.

*Timing of administration was >96 hours (up to 10 days) postexposure.

### Table 3. Safety of VARIZIG (Varicella Zoster Immune Globulin [Human])

| Preferred Term | In Utero–Exposed Newborns (n = 43) | Preterm Infants (n = 80) |
|---------------|-----------------------------------|------------------------|
| AEs | | |
| Participants, No. (%) | 7 (16) | 20 (25) |
| Total AEs, No. | 13 | 58 |
| AEs related to VARIZIG | | |
| Participants, No. (%) | 1 (2) | 1 (1) |
| Participants with related AEs, No. (%) | | |
| Seizure | … | 1 (1) |
| Varicella | 1 (2) | … |
| Serious AEs | | |
| Participants, No. (%) | 5 (12) | 7 (9) |
| Total serious AEs, No. | 5 | 20 |
| Total related serious AEs, No. | 1 | 1 |
| All related serious AEs, No. (%)a | | |
| Seizure | … | 1 (2) |
| Varicella | 1 (2) | … |
| Deaths, No. (%) | | 2 (3) |

**Abbreviations**: AE, adverse event.

aIn the in utero–exposed population, the following serious AEs were considered unrelated to VARIZIG: pneumonia (n = 1), varicella (n = 3).

bIn the preterm infant population, the following serious AEs were considered unrelated to VARIZIG: bronchopulmonary dysplasia, pneumonitis, staphylococcal sepsis, thrombocytopenia (each in 2 participants), and coagulopathy, condition aggravated, seizure, cytomegalovirus infection, disseminated intravascular coagulation, intraventricular hemorrhage, metabolic acidosis, necrotizing enterocolitis, pulmonary hemorrhage, sepsis, and urinary tract infection (each in 1 participant).
Discusison

Despite high levels of varicella vaccination in most communities, varicella still occurs, and the incidence of varicella is likely to remain problematic if nonmedical vaccination exemption rates consistently increase nationwide [21]. Moreover, herpes zoster prevalence has not yet been significantly affected by universal varicella vaccination or supplemental zoster vaccination [22]. As such, VZV remains a threat to high-risk populations.

Prior to the availability of passive immunization, case studies reported that newborns exposed to VZV in utero exhibited a high incidence of clinical infection (24%) and death (31%) [4]. A subsequent retrospective report using passive immunization with VZIG (discontinued in 2006) indicated that 62% of in utero–exposed newborns exhibited symptomatic rash after exposure to varicella, with no varicella-related deaths [7]. For comparison, in immunocompromised children treated with VZIG, the VZV infection rate was 60.4%, with varicella pneumonia occurring in 6.1% of those who developed varicella [16]. In the current analysis, the risk of transmitting varicella to these in utero–exposed newborns was high, and prophylactic administration of VARIZIG may have prevented or attenuated varicella infection in these patients. It is noteworthy that 7 of 38 in utero–exposed newborns still developed varicella, of which 3 were complicated cases (2 with visceral involvement), although there were no varicella-associated deaths. Passive immunization was conceptually designed to work by neutralizing the VZV in vivo; VARIZIG has high titers of neutralizing antibody. However, VZV is highly cell-associated (in the tissue and blood) and can spread directly from cell to cell [23], thus potentially avoiding the neutralizing antibodies introduced by passive immunization. This raises the possibility that the administered antibody can function by arming nonspecific cells of the innate immune system, such as natural killer cells or monocytes [24–26]. It is possible that in the 7 breakthrough cases of varicella, the newborns not only lacked antibody but also innate cellular components of the immune system. This theory could be the basis for future research.

A limitation of our study is that detailed data regarding VZV exposure are lacking in many cases. Although some preterm infant exposures to VZV may have been minimal, it is unknown if each exposure was significant enough to cause varicella. However, investigators determined whether each exposure necessitated VARIZIG administration, which is how VARIZIG is used in clinical practice. As such, we are limited by relying on each investigator’s definition of a significant VZV exposure. It may be that in this cohort, preterm infant exposure to VZV is not as concerning as previously thought due to intrinsic host factors, or that VARIZIG provided protection against VZV infection. As previously noted, of the in utero–exposed newborns with known outcome data, all of the cases of varicella occurred when the mother had varicella (n = 7/23), not herpes zoster (n = 0/6). Although the small number of newborns in these groups limits the conclusions about risk by VZV infection type, it is likely that transplacental passage of maternal antibodies conferred some protection to the subset of infants born to mothers with herpes zoster.

Most in utero–exposed newborns and preterm infants did not receive antiviral prophylaxis concomitant with VARIZIG, while 5% (n = 6/123) received antiviral treatment after developing varicella. In utero–exposed newborns had the highest percentage of concomitant antiviral prophylaxis (28%). However, antiviral prophylaxis was most often given within the first few days of exposure (ie, immediately after birth or when exposure was first reported) while the physician was waiting for receipt of VARIZIG. Often antiviral prophylaxis was discontinued after only 2 days. This use of acyclovir prophylaxis deviates from a report demonstrating a reduced incidence of varicella when acyclovir is given 6–10 days after exposure for 7 days compared with failure of acyclovir prophylaxis that was administered in the first few days after exposure [27].

This analysis has additional limitations. Because of this expanded-access program, which assessed the use of VARIZIG in a real-world setting, there was no control treatment and there was a large amount of missing data measurements. This study did not always distinguish the type of VZV exposure, so the true proportion of varicella vs herpes zoster exposures in each group is unknown. Furthermore, each physician determined whether the exposure qualified for prophylaxis, which probably led to the inclusion of cases with limited exposure and risk of varicella.

Conclusions

These data demonstrate safety in the newborn and preterm infant population, and show that for a variety of exposure types and times, the incidence of varicella and varicella-related complications was similar regardless of the timing of administration of a single dose of intramuscular VARIZIG.

Notes

Acknowledgments. Medical writing assistance, funded by Saol Therapeutics, was provided by Kelly M. Cameron, PhD, ISMPP CMPP, of JB Ashtin, who developed the first draft based on an author-approved outline and assisted in implementing author revisions throughout the editorial process.

Author contributions. All authors participated in the research project conception and design, data analysis, and data interpretation. All authors wrote, edited, reviewed, and approved the manuscript for publication. The data underlying this study belong to Saol Therapeutics. Interested researchers can send data access requests to the following email address: info@saolrx.com.

Financial support. This study was funded by Cangene Corporation, Winnipeg, Canada, the manufacturer and initial owner of VARIZIG (varicella zoster immune globulin, human). Cangene was involved in study design and content. Saol Therapeutics funded the subsequent independent data analysis, interpretation, and writing support, and the decision to submit the article for publication. Saol was involved in the review of the article for medical accuracy, but the final content was left to the discretion of the authors.
Potential conflicts of interest. M. J. L. has served as a consultant and/or scientific advisor for Merck, GlaxoSmithKline, and Saol Therapeutics, and has received research support from Merck and GlaxoSmithKline. J. M. D. has been a consultant and/or scientific advisor for Saol Therapeutics. A. A. G. has a service contract from Merck for laboratory studies of complications of live attenuated VZV vaccines. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References
1. Centers for Disease Control and Prevention. Shingles overview. Available at: https://www.cdc.gov/shingles/about/overview.html. Accessed 27 January 2019.
2. Centers for Disease Control and Prevention. Monitoring the impact of varicella vaccination. Available at: https://www.cdc.gov/chickenpox/surveillance/monitoring-varicella.html. Accessed 27 January 2019.
3. Lopez AS, Zhang J, Marin M. Epidemiology of varicella during the 2-dose varicella vaccination program—United States, 2005–2014. MMWR Morb Mortal Wkly Rep 2016; 65:962–5.
4. Meyers JD. Congenital varicella in term infants: risk reconsidered. J Infect Dis 1974; 129:215–7.
5. Canadian Paediatric Society. Varicella zoster immune globulin use in neonates and infants. Can J Infect Dis 1996; 7:17–8.
6. Straus SE, Ostrow JM, Inchauspe G, et al. NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med 1988; 108:221–37.
7. Miller E, Cradock-Watson JE, Ridehalgh MK. Outcome in newborn babies given anti-varicella-zoster immunoglobulin after perinatal maternal infection with varicella-zoster virus. Lancet 1989; 2:371–3.
8. Recommendations of the Immunization Practices Advisory Committee, Centers for Disease Control. Varicella-zoster immune globulin for the prevention of chickenpox. Ann Intern Med 1984; 100:859–65.
9. Preblud SR. Age-specific risks of varicella complications. Pediatrics 1981; 68:14–7.
10. Simister NE. Placental transport of immunoglobulin G. Vaccine 2003; 21:3365–9.
11. Brunell PA, Gershon AA, Hughes WT, Riley HD Jr, Smith J. Prevention of varicella in high risk children: a collaborative study. Pediatrics 1972; 50:718–22.
12. Brunell PA, Ross A, Miller LH, Kuo B. Prevention of varicella by zoster immune globulin. N Engl J Med 1969; 260:1191–4.
13. Jespersen C, Helmuth IG, Krause TG. Varicella-zoster immunoglobulin treatment in pregnant women in Denmark from 2005 to 2015: descriptive epidemiology and follow-up. Epidemiol Infect 2016; 144:3426–34.
14. Ross AH. Modification of chicken pox in family contacts by administration of gamma globulin. N Engl J Med 1962; 267:369–76.
15. Gershon AA, Steinberg S, Brunell PA. Zoster immune globulin. A further assessment. N Engl J Med 1974; 290:243–5.
16. Zaia JA, Levin MJ, Preblud SR, et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983; 147:737–43.
17. Centers for Disease Control and Prevention. A new product (VarIZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morb Mortal Wkly Rep 2006; 55:209–10.
18. Centers for Disease Control and Prevention. Updated recommendations for use of VarIZIG—United States, 2013. MMWR Morb Mortal Wkly Rep 2013; 62:574–6.
19. VARIZIG (varicella zoster immune globulin [human]). Prescribing information. Roswell, GA: Saol Therapeutics, 2012. Available at: https://varizig.com/VARIZIG_PI.pdf. Accessed 1 March 2019.
20. Levin MJ, Duchon JM, Swamy GK, Gershon AA. Varicella zoster immune globulin (VARIZIG) administration up to 10 days following varicella exposure in pregnant women, immunocompromised participants, and infants: varicella outcomes and safety results from a large, open-label, expanded-access program. PLoS One 2019; 14:e0217749.
21. Mellenior JL, Maxwell CB, Knighton DL, Kris J, Seither R, Black CL. Vaccination coverage for selected vaccines and exemption rates among children in kindergarten—United States, 2017–18 school year. MMWR Morb Mortal Wkly Rep 2018; 67:1115–22.
22. Harpaz R, van Hoek AJ. Point-counterpoint: the Hope-Simpson hypothesis and its implications regarding an effect of routine varicella vaccination on herpes zoster incidence. J Infect Dis 2018; 218(Suppl 2):S57–62.
23. Chen JH, Zhu Z, Gershon AA, Gershon MD. Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster. Cell 2004; 119:915–26.
24. Ito M, Ibata T, Grose C, Starr S. Human leukocytes kill varicella-zoster virus-infected fibroblasts in the presence of murine monoclonal antibodies to virus-specific glycoproteins. J Virol 1985; 54:98–103.
25. Kamiya H, Starr SE, Arbeter AM, Plotkin SA. Antibody-dependent cell-mediated cytotoxicity against varicella-zoster virus-infected targets. Infect Immun 1982; 38:554–7.
26. Tilden AB, Cauda R, Grossi CE, Balch CM, Lokenan AD, Whitley RJ. Demonstration of NK cell-mediated lysis of varicella-zoster virus (VZV)-infected cells: characterization of the effector cells. J Immunol 1986; 136:423–8.
27. Suga S, Yoshikawa T, Ozaki T, Asano Y. Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella. Arch Dis Child 1993; 69:839–42; discussion 42–3.